The new test developed helps improve management of COVID-19 by enabling hospitals to ensure that these patients have access to intensive care.

In low-income communities, identifying COVID-19 patients who are likely to experience severe illnesses is also the need of the hour, because nearly half of these communities in the U.S. lack ICU bed facilities.
The new Single Molecule Array (Simoa) SARS-CoV-2 antigen test developed by David R. Walt, PhD, at Brigham and Women’s Hospital and Harvard University in Boston identifies patients who are likely to need ICU. The test detects and measures blood levels of S1—a protein that is part of the SARS-CoV-2 viral envelope.
Study Results
In 64 COVID-19 patients, researchers evaluated the test’s performance. Of these
23 study participants had undetectable S1 concentrations
23 had low concentrations (6-50 pg/mL), and
18 patients had high concentrations (>50 pg/mL)
Link between S1 concentration and ICU admission
- 77% of the patients with increased S1 concentrations were admitted to the ICU and required intubation within 1 day of presentation at the hospital.
- 52% and 30% of patients with low and undetectable concentrations, respectively, required intensive care.
Advertisements
How do you Stay Safe During COVID-19 Pandemic
- Wash hands after going out or interacting with people
- Wear a filtered mask with the absorbent while surface facing the mouth absorb the germs that you cough out.
- Avoid crowded places.
- Maintain social distancing.
- Avoid eating uncooked meat.
Advertisements